Carregant...
A patient previously treated with ALK inhibitors for central nervous system lesions from ALK rearranged lung cancer: a case report
BACKGROUND: Patients with anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) are now preferentially treated with tyrosine kinase inhibitors (TKIs). However, patients treated with ALK inhibitors end up with acquired resistance. CASE PRESENTATION: We present a patient with...
Guardat en:
| Publicat a: | Onco Targets Ther |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5066989/ https://ncbi.nlm.nih.gov/pubmed/27785052 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S112833 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|